İnsan İmmünoyetmezlik Virüsü-1 HIV-1 İntegraz İnhibitörleri

Yıl 2017, Sayı: 1, 29 - 51, 01.01.2017

Pınar Erkekoğlu Nida Koyuncu

Öz

İnsan immünoyetmezlik virüsü-1 HIV-1 replikasyon için proteaz, revers transkriptaz ve integraza IN ihtiyaç duyar. Son yıllarda, insan immünoyetmezlik sendromunun AIDS tedavisinde HIV-1 IN, antiviral tedavi için önemli bir hedef olarak popülarite kazanmıştır. IN’ye odaklanarak önemli çalışmalar yapılmıştır ve üç yeni ilaç raltegravir, elvitegravir ve dolutegravir Gıda ve İlaç Dairesi’nden FDA onay almıştır. Bu ilaçlar tek veya HIV DNA kopya sayısında daha iyi düşüşler sağlamak için kombine doz rejimleri şeklinde kullanılabilir. Birçok çalışma ile bu ilaçların etkinliği ve güvenliliği hep daha önce tedavi görmemiş, hem de daha önce tedavi gören HIV hastalarında belirlenmiştir. Son zamanlardaki uygulama kılavuzlarına göre IN inhibitörü ilaç rejimleri daha önce tedavi görmemiş hastalarda ilk basamak tedavi olarak kabul edilmektedir. Henüz geliştirilmekte olan birçok IN inhibitörü de doğal veya sentetik bulunmaktadır. Bu maddelerin de etkinlikleri ve yan etkileri farklı çalışmalar ile araştırılmaktadır. Bu çalışmaların en önemli hedefleri etkinliği arttırarak, rezistans profillerini geliştirmek ve ilaç uygulama sıklığını ve yan etkilerini azaltmaktır. Bu derlemede, kullanımda olan ve yeni bulunan IN inhibitörlerinin farmakolojik ve toksikolojik etkilerinden söz edilecektir.

Anahtar Kelimeler

HIV, AIDS, integraz, raltegravir, diketo asitler

Human Immunodeficiency Virus-1 HIV-1 Integrase Inhibitors

Öz

Human immunodeficiency virus-1 HIV-1 requires protease, reverse transcriptase and integrase IN for replication. In the last decades, HIV-1 IN is gaining popularity as a target for the antiviral therapy of acqired immunodeficiency syndrome AIDS . Substantial work focusing on IN has been performed and three new drugs raltegravir, elvitegravir and dolutegravir received approval from Food and Drug Administration FDA . These drugs can be used in single or combined dose regimens to obtain better reduction in HIV DNA copies. The efficacy and safety of these three drugs in treatment-naïve and experienced HIV-infected patients have been established by multiple studies. Based on the current practice guidelines, IN inhibitor-based drug regimens are considered as one of the first-line therapies for treatment-naïve HIV-infected patients. There are also several new IN inhibitors natural or synthetic in development. These efficiancies and side effects of these substances are now being investigated by different studies. The most important goals of these studies are to increase the efficacy, to improve the resistance profiles and to decrease the frequency of drug administration and side effects. This review will focus on the pharmacology and toxicology of IN inhibitors in use and the newly discovered IN inhibitors.

Anahtar Kelimeler

HIV, AIDS, integrase, raltegravir, diketo acids

Kaynakça

• Sepkowitz KA: AIDS—the first 20 years. New England Journal of Medicine 2001, 344(23):1764–1772.
• Yoshimura K: Current status of HIV/AIDS in the ART era. Journal of Infections and Chemotherapy 2016 pii: S1341-321X(16)30198-301912.
• Sheets RL, Zhou T, Knezevic I: Review of efficacy trials of HIV-1/AIDS vaccines and regulatory lessons learned: A review from a regulatory perspective. Biologicals 2016 44(2):73-89.
• Cary DC, Fujinaga K, Peterlin BM: Molecular mechanisms of HIV latency. Jornal of Clinical Investigations 2016, 126(2):448-454.
• Spivak AM, Planelles V. HIV-1 Eradication: Early Trials (and Tribulations). Trends in Molecular Medicine 2016, 22(1):10-27.
• Sprenger HG, Bierman WF, van der Werf TS, Gisolf EH, Richter C: A systematic review of a single-class maintenance strategy with nucleoside/nucleotide reverse transcriptase inhibitors in HIV/AIDS. Antiviral Therapy 2014, 19(7):625-36.
• Schafer JJ, Short WR: Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review. Antiviral Therapy 2012, 17(8):1495-1502.
• Reynolds C, de Koning CB, Pelly SC, van Otterlo WA, Bode ML: In search of atreatment for HIV--current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Chemical Society Reviews 2012, 41(13):4657-4670.
• Kurt Yilmaz N, Swanstrom R, Schiffer CA: Improving Viral Protease Inhibitors to Counter Drug Resistance. Trends in Microbiology 2016, 24(7):547-557.
• Henrich TJ, Kuritzkes DR: HIV-1 entry inhibitors: recent development and clinical use. Current Opinions in Virology 2013, 3(1):51-57.
• Park TE, Mohamed A, Kalabalik J, Sharma R: Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Reviews in Anti Infectious Therapy 2015, 13(10):1195-1212.
• Larson KB, Wang K, Delille C, Otofokun I, Acosta EP.: Pharmacokinetic enhancers in HIV therapeutics. Clinical Pharmacokinetics 2014, 53(10):865-872.
• Lee FJ, Amin J, Carr A: Limited reporting of major harms in studies of initial combination antiretroviral therapy: a systematic review. AIDS. 2015, 29(8):921-929.
• Baril JG, Angel JB, Gill MJ, Gathe J, Cahn P, van Wyk J, Walmsley S: Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. PLoS One. 2016, 11(2):e0148231.
• Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A, Rusconi S, Santoro MM, Clementi M, Perno CF, d’Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, Calcagno A, Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A: An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. New Microbiology 2015, 38(4):443-490.
• Park TE, Mohamed A, Kalabalik J, Sharma R: Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Reviews in Anti Infectious Therapy 2015, 13(10):1195-1212.
• Blanco JL, Whitlock G, Milinkovic A, Moyle G: HIV integrase inhibitors: a new era in the treatment of HIV. Expert Opinions in Pharmacotherapy 2015, 16(9):1313-1324.
• Esposito F, Tramontano E: Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: single and dual active site inhibitors. Antiviral Chemistry and Chemotherapy 2014, 23(4):129-144.
• Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, Davies DR: Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proceedings of the National Academy of Sciences U S A 1999, 96(23):13040-13043.
• Diamond TL, Bushman FD: Role of metal ions in catalysis by HIV integrase analyzed using a quantitative PCR disintegration assay. Nucleic Acids Research 2006, 34(21):6116-6125.
• Krishnan L, Engelman A: Retroviral integrase proteins and HIV-1 DNA integration. Journal of Biological Chemistry 2012, 287(49):40858-40866.
• Hu WS, Hughes SH: HIV-1 reverse transcription. Cold Spring Harbour Perspective Medicine 2012, 2(10). pii: a006882.
• Métifiot M, Johnson BC, Kiselev E, Marler L, Zhao XZ, Burke TR Jr, Marchand C, Hughes SH, Pommier Y: Selectivity for strand-transfer over 3’-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site. Nucleic Acids Research 2016, 44(14):6896-6906.
• Chen JC, Krucinski J, Miercke LJ, Finer-Moore JS, Tang AH, Leavitt AD, Stroud RM: Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proceedings of the National Academy of Sciences U S A 2000, 97(15):8233-8238.
• Wang JY, Ling H, Yang W, Craigie R: Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO Journal 2001, 20(24):7333-7343.
• Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, Princiotta MF, Bennink JR, Krausslich HG, Yewdell JW: Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proceedings of the National Academy of Sciences U S A 2000, 97(24):13057-13062.
• Diamond TL, Bushman FD: Role of metal ions in catalysis by HIV integrase analyzed using a quantitative PCR disintegration assay. Nucleic Acids Research 2006, 34(21):6116-6125.
• Yi J, Asante-Appiah E, Skalka AM: Divalent cations stimulate preferential recognition of a viral DNA end by HIV-1 integrase. Biochemistry. 1999, 38(26):8458-8468.
• Bacchi A, Carcelli M, Compari C, Fisicaro E, Pala N, Rispoli G, Rogolino D, Sanchez TW, Sechi M, Sinisi V, Neamati N: Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. Journal of Medicinal Chemistry 2011, 54(24):8407-8420.
• Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR: Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994, 266:1981–1986.
• Engelman A, Craigie R: Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity. Journal of Virology 1995, 69(9):5908-5911. virus type 1 integrase. Journal of Virology 1997, 71(9):7005-7011.
• King PJ, Lee DJ, Reinke RA, Victoria JG, Beale K, Robinson WE Jr: Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors. Virology 2003, 306(1):147-161.
• Hazuda DJ: HIV integrase as a target for antiretroviral therapy. Current Opinions in HIV AIDS. 2012, 7(5):383-389.
• Charpentier C, Piketty C, Laureillard D, Tisserand P, Si-Mohamed A, Weiss L, Bélec L: Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31(2):129-133.
• Levin A, Armon-Omer A, Rosenbluh J, Melamed-Book N, Graessmann A, Waigmann E, Loyter A: Inhibition of HIV-1 integrase nuclear import and replication by a peptide bearing integrase putative nuclear localization signal. Retrovirology 2009, 6:112.
• Maes M, Loyter A, Friedler A: Peptides that inhibit HIV-1 integrase by blocking its protein-protein interactions. FEBS Journal 2012, 279(16):2795-2809.
• Xue W, Liu H, Yao X: Molecular mechanism of HIV-1 integrase-vDNA interactions and strand transfer inhibitor action: a molecular modeling perspective. Journal of Computitional Chemistry 2012, 33(5):527-536.
• Drug Approval Package. Drug Name: Isentress (raltegravir) 400mg Tablets Company: Merck & Company, Inc. İnternet Adresi: 022145http://www.accessdata.fda.gov/ drugsatfda_docs/nda/2007/022145_Isentress.cfm [Website]
• Hughes CA, Robinson L, Tseng A, MacArthur RD: New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opinion in Pharmacotherapy 2009, 10(15):2445-2466.
• Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H; Protocol 004 Part II Study Team: Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment- naive patients with HIV-1 infection: results of a 48-week controlled study”. Journal of Acquired Immune Deficiency Syndrome 2007, 46 (2):125–133.
• AIDSinfo Drug Database. Raltegravir. İnternet adresi: https://aidsinfo.nih.gov/drugs/420/ raltegravir/0/patient. [Website]
• Highlights of Prescribing Information. Isentress® (Raltegravir) film-coated tablets, for oral use. ISENTRESS® (raltegravir) chewable tablets, for oral use. ISENTRESS® (raltegravir) for oral suspension. İnternet sitesi: https://www.merck.com/product/usa/ pi_circulars/i/isentress/isentress_pi.pdf)
• Blonk MI, Colbers AP, Hidalgo-Tenorio C, Kabeya K, Weizsäcker K, Haberl AE, Moltó J, Hawkins DA, van der Ende ME, Gingelmaier A, Taylor GP, Ivanovic J, Giaquinto C, Burger DM: Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women PANNA Network; PANNA Network. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy. Clinical Infectious Diseases 2015, 61(5):809-816.
• Fernández-Montero JV: Once-daily raltegravir moving ahead. AIDS Reviews 2013, 15(4):238-239.
• Sax P E, Dejesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK: Gs-Us-236-0102 Study T: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co- formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks”. The Lancet. 2012, 379 (9835): 2439–2448.
• Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe, Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M: Broad Anti-Retroviral Activity and Resistance Profile of a Novel Human Immunodeficiency Virus Integrase Inhibitor, Elvitegravir (JTK-303/GS-9137). Journal of Virology, 82(2):764–774.
• Highlights of Prescribing Information Stribild. İnternet sitesi: http://www.gilead.com/~/ media/files/pdfs/medicines/hiv/stribild/stribild_pi.pdf. [Website]
• Elvitegravir (Vitekta) for HIV. Medical Letters on Drugs Theray 2016, 58(1486):10-11.
• Raffe S, Fisher M: The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV. Expert Opinion on Drug Metabolism and Toxicology 2015, 11(3):427-435.
• Deeks ED: Elvitegravir: a review of its use in adults with HIV-1 infection. Drugs 2014, 74(6):687-697.
• Highlights of Prescribing Information. Tivicay. İnternet sitesi http://www.accessdata.fda. gov/drugsatfda_docs/label/2013/204790lbl.pdf.
• Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min, S; extended SPRING-2 Study Group: Once- daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV- 1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non- inferiority trial. The Lancet Infectious Diseases 2013, 13 (11): 927–935.
• Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G; SINGLE Investigators: Dolutegravir plus abakavir-lamivudine for the treatment of HIV-1 infection. New England Journal of Medicine 2013, 369(19):1807-1818.
• Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S; ING114915 Study Team: Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open- label phase 3b study. The Lancet. 2014, 383(9936):2222-2231.
• Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nichols G, Yeo JM; VIKING-3 Study Group: Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. Journal of Infectious Diseases 2014, 210(3):354-362.
• [Dolutegravir (Tivicay) orally]. Journal of Pharmacy Belgium 2015, (3):47-48.
• Kandel CE, Walmsley SL: Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Journal of Drug Design Development and Therapy 2015, 9:3547-3555.
• Henao-Mejia J, Góez Y, Patiño P, Rugeles MT: Diketo acids derivatives as integrase inhibitors: the war against the acquired immunodeficiency syndrome. Recent Patents On Anti-İnfective Drug Discovery 2006, 1(2):255-265.
• Zhao G, Wang C, Liu C, Lou H: New developments in diketo-containing inhibitors of HIV-1 integrase. Mini Reviews in Medicinal Chemistry 2007, 7(7):707-725.
• Pescatori L, Métifiot M, Chung S, Masoaka T, Cuzzucoli Crucitti G, Messore A, Pupo G, Madia VN, Saccoliti F, Scipione L, Tortorella S, Di Leva FS, Cosconati S, Marinelli L, Novellino E, Le Grice SF, Pommier Y, Marchand C, Costi R, Di Santo R: N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase. Journal of Medicinal Chemistry 2015, 58(11):4610-4623.
• Brigo A, Lee KW, Fogolari F, Mustata GI, Briggs JM: Comparative molecular dynamics simulations of HIV-1 integrase and the T66I/M154I mutant: binding modes and drug resistance to a diketo acid inhibitor. Proteins 2005, 59(4):723-741.
• Henao-Mejia J, Góez Y, Patiño P, Rugeles MT: Diketo acids derivatives as integrase inhibitors: the war against the acquired immunodeficiency syndrome. Recent Pat Antiinfectious Drug Discovery 2006, 1(2):255-265.
• Crosby DC, Lei X, Gibbs CG, McDougall BR, Robinson WE, Reinecke MG: Design, synthesis, and biological evaluation of novel hybrid dicaffeoyltartaric/diketo acid and tetrazole-substituted L-chicoric acid analogue inhibitors of human immunodeficiency virus type 1 integrase. Journal of Medicinal Chemistry 2010, 53(22):8161-8175.
• Nair V, Chi G: HIV integrase inhibitors as therapeutic agents in AIDS. Reviews in Medical Virology 2007, 17(4):277-295.
• Zahm JA, Bera S, Pandey KK, Vora A, Stillmock K, Hazuda D, Grandgenett DP: Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. Antimicrobial Agents and Chemotherapy 2008, 52(9):3358-3368.
• Pandey KK, Bera S, Zahm J, Vora A, Stillmock K, Hazuda D, Grandgenett DP: Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. Journal of Virology 2007, 81(22):12189-12199.
• Pais GC, Zhang X, Marchand C, Neamati N, Cowansage K, Svarovskaia ES, Pathak VK, Tang Y, Nicklaus M, Pommier Y, Burke TR Jr: Structure activity of 3-aryl-1,3-diketo- containing compounds as HIV-1 integrase inhibitors. Journal of Medicinal Chemistry 2002, 45(15):3184-3194.
• Rao GS, Bhatnagar S, Ahuja V: Structure-based design of a novel peptide inhibitor of HIV-1 integrase: a computer modeling approach. Journal of Biomolecular Structure and Dynamics. 2002, 20(1):31-38.
• Cuzzucoli Crucitti G, Métifiot M, Pescatori L, Messore A, Madia VN, Pupo G, Saccoliti F, Scipione L, Tortorella S, Esposito F, Corona A, Cadeddu M, Marchand C, Pommier Y, Tramontano E, Costi R, Di Santo R: Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain. Journal of Medicinal Chemistry 2015, 58(4):1915-1928.
• Robinson WE Jr: L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350). Antiviral Research 1998, 39(2):101-111.
• McDougall B, King PJ, Wu BW, Hostomsky Z, Reinecke MG, Robinson WE Jr: Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrobial Agents and Chemotherapy 1998, 42(1):140-146.
• Bonn D: Green coffee beans may yield new class of anti-HIV-1 agents. The Lancet. 1998, 352(9133):1039.
• McDougall B, King PJ, Wu BW, Hostomsky Z, Reinecke MG, Robinson WE Jr: Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrobal Agents and Chemotherapy 1998 42(1):140-163.
• Robinson WE Jr, Reinecke MG, Abdel-Malek S, Jia Q, Chow SA: Inhibitors of HIV-1 replication that inhibit HIV integrase. Procedings of National Academy of Sciences U S A. 1996, 93(13):6326-6331.
• Adamoli R: Unconventional therapies in HIV infection: a working perspective. XII Natinal Conference ANLAIDS. 1998.
• Fachinetto JM, Bagatini MD, Durigon J, da Silva ACF, TedescoI SB: Anti-proliferative effect of infusions of Achyrocline satureioides on the Allium cepa cell cycle. Brazilian Journal of Pharmacognosy 2007, 17:4954.
• Johnston MI, Hoth DF: Present status and future prospects for HIV therapies. Science 1993, 260(5112):1286-1293.
• Chi G, Nair V: Synthetic approaches to nuclease-resistant, nonnatural dinucleotides of anti-HIV integrase interest. Nucleosides Nucleotides Nucleic Acids 2005, 24(10- 12):1449-1468.
• Taktakishvili M, Neamati N, Pommier Y, Nair V: Recognition and inhibition of HIV integrase by a novel dinucleotide. Bioorganic Medicinal Chemistry Letters 2000, 10(3):249-251.
• Cherepanov P, Esté JA, Rando RF, Ojwang JO, Reekmans G, Steinfeld R, David G, De Clercq E, Debyser Z: Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Molecular Pharmacology 1997, 52(5):771-780.
• Scomparin A, Polyak D, Krivitsky A, Satchi-Fainaro R.: Achieving successful delivery of oligonucleotides--From physico-chemical characterization to in vivo evaluation. Biotechnology Advances 2015, 33(6 Pt 3):1294-1309.
• Van Aerschot A: Oligonucleotides as antivirals: dream or realistic perspective? Antiviral Research 2006, 71(2-3):307-316.
• Turner JJ, Fabani M, Arzumanov AA, Ivanova G, Gait MJ: Targeting the HIV-1 RNA leader sequence with synthetic oligonucleotides and siRNA: chemistry and cell delivery. Biochimie Biophys Acta 2006, 1758(3):290-300.
• Aiello F, Brizzi A, Garofalo A, Grande F, Ragno G, Dayam R, Neamati N: Synthesis of novel thiazolothiazepine based HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry 2004, 12(16):4459-4466.
• Neamati N, Turpin JA, Winslow HE, Christensen JL, Williamson K, Orr A, Rice WG, Pommier Y, Garofalo A, Brizzi A, Campiani G, Fiorini I, Nacci V: Thiazolothiazepine inhibitors of HIV-1 integrase. Journal of Medicinal Chemistry 1999, 42(17):3334-3341.
• Reddy MV, Rao MR, Rhodes D, Hansen MS, Rubins K, Bushman FD, Venkateswarlu Y, Faulkner DJ: Lamellarin alpha 20-sulfate, an inhibitor of HIV-1 integrase active against HIV-1 virus in cell culture. Journal of Medicinal Chemistry 1999, 42(11):1901-1907.
• Ridley CP, Reddy MV, Rocha G, Bushman FD, Faulkner DJ: Total synthesis and evaluation of lamellarin alpha 20-Sulfate analogues. Bioorganic & Medicinal Chemistry 2002, 10(10):3285-3290.
• Kamiyama H, Kubo Y, Sato H, Yamamoto N, Fukuda T, Ishibashi F, Iwao M: Synthesis, structure-activity relationships, and mechanism of action of anti-HIV-1 lamellarin α 20-sulfate analogues. Bioorganic & Medicinal Chemistry 2011, 19(24):7541-7550.
• De Clercq E: Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Medical Research Reviews 2000, 20(5):323-349.
• Hazuda D, Blau CU, Felock P, Hastings J, Pramanik B, Wolfe A, Bushman F, Farnet C, Goetz M, Williams M, Silverman K, Lingham R, Singh S: Isolation and characterization of novel human immunodeficiency virus integrase inhibitors from fungal metabolites. Antiviral Chemistry and Chemotherapy 1999, 10(2):63-70.
• Rowley DC, Hansen MS, Rhodes D, Sotriffer CA, Ni H, McCammon JA, Bushman FD, Fenical W: Thalassiolins A-C: new marine-derived inhibitors of HIV cDNA integrase. Bioorganic & Medicinal Chemistry 2002, 10(11):3619-3625.
• Deprez E, Barbe S, Kolaski M, Leh H, Zouhiri F, Auclair C, Brochon JC, Le Bret M, Mouscadet JF: Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Molecular Pharmacology 2004, 65(1):85-98.
• Mekouar K, Mouscadet JF, Desmaële D, Subra F, Leh H, Savouré D, Auclair C, d’Angelo J: Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. Journal of Medical Chemistry 1998, 41(15):2846-2857.
• Eich E, Pertz H, Kaloga M, Schulz J, Fesen MR, Mazumder A, Pommier Y: (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virüs type-1 integrase. Bioorganic & Medicinal Chemistry 1996, 39(1):86-95.
• Carteau S, Mouscadet JF, Goulaouic H, Subra F, Auclair C: Effect of topoisomerase inhibitors on the in vitro HIV DNA integration reaction. Biochem Biophys Res Commun. 1993, 192(3):1409-1414.
• Fesen MR, Kohn KW, Leteurtre F, Pommier Y: Inhibitors of human immunodeficiency virus integrase. Proceedings of National Academy of Sciences U S A. 1993, 90(6):2399- 2403.
• Weinberg JB, Shugars DC, Sherman PA, Sauls DL, Fyfe JA: Cobalamin inhibition of HIV-1 integrase and integration of HIV-1 DNA into cellular DNA. Biochemistry and Biophys Research Communications 1998, 246(2):393-397.
• Weinberg JB, Sauls DL, Misukonis MA, Shugars DC:Inhibition of productive human immunodeficiency virus-1 infection by cobalamins. Blood 1995, 86(4):1281-1287.
• Bacchi A, Carcelli M, Compari C, Fisicaro E, Pala N, Rispoli G, Rogolino D, Sanchez TW, Sechi M, Sinisi V, Neamati N: Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. Journal of Medicinal Chemistry 2011, 54(24):8407- 8420. virus type 1 integrase. Journal of Virolgy 1997, 71(9):7005-7011.
• Chang EL, Simmers C, Knight DA. Cobalt Complexes as Antiviral and Antibacterial Agents. Pharmaceuticals 2010, 3:1711-1728.
• Kowalska JD, Oprea C, de Witt S, Pozniak A, Gökengin D, Youle M, Lundgren JD, Horban A; ECEE Network Group: Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration - a comprehensive meeting report. HIV Medicine 2016. doi: 10.1111/hiv.12436 (basımda).
• Vandegraaff N, Kumar R, Hocking H, Burke TR Jr, Mills J, Rhodes D, Burrell CJ, Li P: Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrobial Agents and Chemotherapy 2001, 45(9):2510-2516.
• Esté JA, Cabrera C, Schols D, Cherepanov P, Gutierrez A, Witvrouw M, Pannecouque C, Debyser Z, Rando RF, Clotet B, Desmyter J, De Clercq E: Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Molecular Pharmacolgy 1998, 53(2):340-345.
• Bodiwala HS, Sabde S, Gupta P, Mukherjee R, Kumar R, Garg P, Bhutani KK, Mitran D, Singh IP: Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5. Bioorganic & Medicinal Chemistry 2011, 19(3):1256-1263.
• Koh Y, Haim H, Engelman A: Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity. Antimicrobial Agents and Chemotherapy 2011, 55(1):42-49.
• Manyeruke MH, Olomola TO, Majumder S, Abrahams S, Isaacs M, Mautsa N, Mosebi S, Mnkandhla D, Hewer R, Hoppe HC, Klein R, Kaye PT: Synthesis and evaluation of 3-hydroxy-3-phenylpropanoate ester–AZT conjugates as potential dual-action HIV-1 Integrase and Reverse Transcriptase inhibitors. Bioorganic & Medicinal Chemistry 2015, 23(24):7521-7528.